Acorda Therapeutics Company Profile (NASDAQ:ACOR)

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

Acorda Therapeutics, Inc. (NASDAQ:ACOR) released its quarterly earnings results on Thursday, July, 27th. The company reported $0.29 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.13 by $0.16. The company had revenue of $139.40 million for the quarter, compared to analyst estimates of $139.81 million. Acorda Therapeutics had a negative net margin of 8.02% and a negative return on equity of 6.37%. The firm's revenue was up 9.3% on a year-over-year basis. During the same quarter last year, the business earned $0.07 earnings per share. View Acorda Therapeutics' Earnings History.

Acorda Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Acorda Therapeutics.

9 brokerages have issued 1 year target prices for Acorda Therapeutics' stock. Their forecasts range from $18.00 to $35.00. On average, they expect Acorda Therapeutics' share price to reach $23.67 in the next twelve months. View Analyst Ratings for Acorda Therapeutics.

Here are some recent quotes from research analysts about Acorda Therapeutics stock:

• 1. Stifel Nicolaus analysts commented, "Alexion (ALXN) reported 2Q17 sales/earnings and provided a business update (PDF) to investors. The company had a strong 2Q17, reporting sales of $912M and non-GAAP EPS of $1.56, beating OPCO by 9% and 25% respectively. The strong beat was partially attributable to favorable one-offs in 1H17, with 2H17 expected to see weaker growth, which was well flagged by the company. The pipeline keeps moving along with a positive opinion for Soliris rMG in the EU in June and a PDUFA date of Oct. 23, 2017. We were particularly struck by new management’s ability to stabilize the business, provide transparency and the continuing strong fundamentals." (7/28/2017)
• 2. According to Zacks Investment Research, "Acorda’s key multiple sclerosis drug Ampyra is facing several patent challenges. Recently a district court invalidated four patents of, Ampyra, thereby making way for generic versions of the drug. Sales Ampyra also declined sequentially in the quarter. The company’s share price underperformed the industry so far this year. With Ampyra facing patent issues, focus has shifted to the company’s late stage parkinson’s candidates Inbrija (formerly known as CVT-301) and tozadenant. However, the company recently submitted regulatory applications for Inbrija in the U.S. and plans to file for the same in the EU by the end of 2017. Meanwhile, Acorda is working on expanding its pipeline by entering into deals and pursuing acquisitions. Estimates have been stable lately ahead of the company’s Q2 earnings release. The company has negative record of earnings surprises in recent quarters." (7/19/2017)
• 3. Cowen and Company analysts commented, "ACOR released Q4 Ampyra revenue and provided 2017 Ampyra guidance, both just." (1/9/2017)

Some companies that are related to Acorda Therapeutics include Insmed (INSM), Array BioPharma (ARRY), NovoCure Limited (NVCR), Aerie Pharmaceuticals (AERI), MyoKardia (MYOK), Intercept Pharmaceuticals (ICPT), Acceleron Pharma (XLRN), Radius Health (RDUS), Lexicon Pharmaceuticals (LXRX), Clinigen Group PLC (CLIN), Sangamo Therapeutics (SGMO), Dynavax Technologies Corporation (DVAX), Ascendis Pharma A/S (ASND), Dermira (DERM), Xencor (XNCR), NeuroDerm (NDRM), Omeros Corporation (OMER) and Epizyme (EPZM).

Acorda Therapeutics' management team includes the folowing people:

• Ron Cohen M.D., President,Chief Executive Officer, Director
• Richard P. Batycky Ph.D., Chief Technology Officer and Site Head
• David Lawrence, Chief Business Operations, Principal Accounting Officer
• Andrew R. Blight Ph.D., Chief Scientific Officer
• Jane Wasman J.D., President - International, General Counsel, Corporate Secretary
• Burkhard Blank M.D., Chief Medical Officer
• Andrew Hindman, Chief Business Development Officer
• Lauren M. Sabella, Chief Commercial Officer
• Barry E. Greene, Independent Director
• Peder K. Jensen M.D., Independent Director

Acorda Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include SCOPIA CAPITAL MANAGEMENT LP (18.20%), SCOPIA CAPITAL MANAGEMENT LP (16.50%), FMR LLC (15.23%), Vanguard Group Inc. (9.38%), State Street Corp (5.31%) and Dimensional Fund Advisors LP (5.16%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Andrew Blight, Barry E Greene, David Lawrence, Enrique J Carrazana, Ian F Smith, Jane Wasman, Lauren M Sabella, Lorin Randall, Michael W Rogers, Richard P Batycky, Ron Cohen, Scopia Capital Management Lp and Steven M Rauscher. View Institutional Ownership Trends for Acorda Therapeutics.

Acorda Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Public Employees Retirement Association of Colorado, Prudential Financial Inc., Alliancebernstein L.P., Schwab Charles Investment Management Inc., Gotham Asset Management LLC, Dupont Capital Management Corp, KBC Group NV and Public Sector Pension investment Board. Company insiders that have sold Acorda Therapeutics stock in the last year include Andrew A Hindman, Barry E Greene, David Lawrence, Jane Wasman, Lorin Randall, Richard P Batycky and Ron Cohen. View Insider Buying and Selling for Acorda Therapeutics.

Acorda Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Dimensional Fund Advisors LP, RA Capital Management LLC, Goldman Sachs Group Inc., Northern Trust Corp, FMR LLC, Spark Investment Management LLC and Vanguard Group Inc.. Company insiders that have bought Acorda Therapeutics stock in the last two years include Ron Cohen and Scopia Capital Management Lp. View Insider Buying and Selling for Acorda Therapeutics.

Shares of Acorda Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Acorda Therapeutics stock can currently be purchased for approximately $23.45.